Remove 2014 Remove Patients Remove Physicians Remove Safety
article thumbnail

PhRMA lies to protect pharma profits

World of DTC Marketing

In the past 12 months, PhRMA and closely allied groups spent at least $57 million — $19 million of it since July — on TV , cable , radio , and social media ads opposing price negotiations, according to monitoring by the advocacy group Patients for Affordable Drugs. First, let’s clarify how the bill saves taxpayers billions.

Pharma 255
article thumbnail

How one pharma “family business” places patients first

pharmaphorum

And just as a family business thrives on its connection to the community, Chiesi is committed to connecting to the global patient community. We try to have a very long-term orientation because we believe that aligns our objectives very well with the objectives of society and the patients we serve, and it makes us a stable business.”.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Collaboration with Janssen and Eli Lilly to address lack of paediatric medications

Pharmaceutical Technology

In recent years, with the advent of biologics and novel therapeutic targets such as anti-TNF, anti-interleukin, and anti-integrin, there has been a steady increase in the number of agents approved to treat inflammatory bowel diseases (IBD), which has provided physicians with an increasing number of options to treat Crohn’s disease (CD).

Medical 59
article thumbnail

Relief for Amylyx as FDA clears controversial ALS drug Relyvrio

pharmaphorum

Patient organisations have been celebrating the FDA approval yesterday of Amylyx’ amyotrophic lateral sclerosis (ALS) therapy Relyvrio, after not one but two advisory committee meetings that arrived at different conclusions about the drug.

FDA 77
article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

When patients experience intense emotion, either positive or negative, they are rendered unconscious. In order to bring it to market, a special program called Risk Evaluation and Mitigation Strategy (REMS) had to be put in place, where only eligible patients could access the drug through a very strict process.

article thumbnail

The future of medical cannabis development in Europe

European Pharmaceutical Review

In many European countries physicians can now prescribe medical cannabis for an array of chronic health conditions, including chronic pain, mental health disorders and neurological conditions. This will lead to a higher proportion of these medicines becoming licensed, benefitting a larger number of patients.

Medical 81
article thumbnail

The imperative of fridge-free vaccines

European Pharmaceutical Review

A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient. About 800 million humans are injected with vaccines every year” Most vaccines in use today are relatively cheap to make and are injected into patients with mass‑produced and inexpensive (five-cent) disposable syringes.